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ARTICLE
Exploiting metabolic acidosis in solid cancers using
a tumor-agnostic pH-activatable nanoprobe for
fluorescence-guided surgery
F. J. Voskuil 1,13, P. J. Steinkamp 2,13, T. Zhao3, B. van der Vegt 4, M. Koller2, J. J. Doff4, Y. Jayalakshmi3,
J. P. Hartung5, J. Gao 6,7, B. D. Sumer 6✉, M. J. H. Witjes1, G. M. van Dam 2,8✉ & the SHINE study group*
Cancer cell metabolism leads to a uniquely acidic microenvironment in solid tumors, but
exploiting the labile extracellular pH differences between cancer and normal tissues for
clinical use has been challenging. Here we describe the clinical translation of ONM-100, a
nanoparticle-based fluorescent imaging agent. This is comprised of an ultra-pH sensitive
amphiphilic polymer, conjugated with indocyanine green, which rapidly and irreversibly dis-
sociates to fluoresce in the acidic extracellular tumor microenvironment due to the
mechanism of nanoscale macromolecular cooperativity. Primary outcomes were safety,
pharmacokinetics and imaging feasilibity of ONM-100. Secondary outcomes were to deter-
mine a range of safe doses of ONM-100 for intra-operative imaging using commonly used
fluorescence camera systems. In this study (Netherlands National Trial Register #7085), we
report that ONM-100 was well tolerated, and four solid tumor types could be visualized both
in- and ex vivo in thirty subjects. ONM-100 enables detection of tumor-positive resection
margins in 9/9 subjects and four additional otherwise missed occult lesions. Consequently,
this pH-activatable optical imaging agent may be clinically beneficial in differentiating
previously unexploitable narrow physiologic differences.
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Cancer specific fluorescence-guided imaging has tradition-ally involved fluorophore-labeled small molecules, anti-bodies, nanobodies, peptides, or nanoparticles against cell
surface receptors1–9. Despite promising results, such strategies
often lack broad tumor applicability due to the diversity of
oncogenotypes and phenotypes10,11. In contrast, extracellular
cancer acidosis—a ubiquitous consequence of cell proliferation
and growth in cancer—could serve as a generic target in a variety
of solid tumors12,13. While virtually all solid cancers demonstrate
low extracellular pH relative to the tightly regulated pH of the
normal extracellular compartment, the pH is spatiotemporally
variable. The variability in tumor pH is affected by tumor
intrinsic factors, such as aerobic and anaerobic glycolysis,
hypoxia, angiogenesis, and perfusion, which interact in unpre-
dictable ways with different areas of a given cancer resulting in a
pH between 5.8 and 7.4 at different times14,15.
To exploit the dysregulated tumor milieu, a series of tunable
pH-sensitive amphiphilic polymers have been developed that
generate a fluorescent output in response to a reduction in pH16.
In an aqueous solution, the polymers self-assemble into
nanometer-sized micelles. Fluorophores, such as indocyanine
green (ICG), sequester within the hydrophobic segments of the
micellar core leading to homoFRET fluorescence quenching17.
Cooperative dissociation of the micelles at a tunable pH threshold
releases the individual unimers, thereby unquenching the fluor-
escent dye (Fig. 1). The discrete cooperative response of the
polymers to pH is a unique nanoscale phenomenon with two
distinguished characteristics for pH sensing18. First, the coop-
erativity, with a Hill’s coefficient as high as 51, makes fluorescence
activation a thresholded maximal event: fluorescence is either
completely off or completely on above and below a sharply
demarcated pH point. Second, the activation is irreversible due to
the capture of dissociated unimers by the proteins in the tumor
microenvironment which prevent reformation of the micelles that
would quench the fluorescence. When progressive fluorescence
activation in zones of acidosis is integrated over time, a stable,
discrete fluorescent labeling of tumors is achieved19.
Human patients vary widely with respect to body habitus and
underlying metabolic and nutritional status, while their cancers
vary by type, size, and mutational status20. These extrinsic and
intrinsic tumor variables compound accurate tumor pH
detection. Despite Otto Warburg first describing deregulated
cancer metabolism over a century ago, it has not been utilized
clinically. We therefore hypothesized that the nanoscale coop-
erativity of the pH-responsive polymers could be leveraged for
fluorescence-guided tumor identification and that the irrever-
sible binary activation could provide novel information not
obtainable through routine surgical standards of care.
In this clinical study, ONM-100, an intravenously administered
imaging agent based on pH-sensitive polymers, was investigated in
human patients. The results presented below demonstrate ONM-
100’s ability to detect, otherwise missed, tumor-positive surgical
margins and occult disease. All four of the investigated solid tumor
types were visualized by tumor-agnostic fluorescence. The potential
of ONM-100 in clinical decision making during and post-surgery
needs to be confirmed by an additional Phase II clinical study.
Results
Summary of safety and pharmacokinetic evaluations of ONM-
100. The primary outcomes of this Phase 1 study were the safety,
pharmacokinetics, and imaging feasibility of a single intravenous
dose of ONM-100 administered to patients with solid cancer 24 ±
8 h prior to undergoing standard surgery. The study procedures
are shown in Fig. 2. Thirty subjects with four different solid
tumor types (head and neck squamous cell carcinoma [HNSCC],
n= 13, breast cancer [BC], n= 11, esophageal cancer [EC], n= 3,
and colorectal cancer [CRC]), n= 3 were enrolled.
Eight subjects with HNSCC and seven with BC were included
in the dose-escalating Phase 1a study (secondary outcome). To
evaluate the tumor-agnostic imaging feasibility further with
ONM-100, 15 additional subjects with four different tumor
types (HNSCC, BC, EC, or CRC) were dosed in Phase 1b with
an optimal dose determined in Phase 1a (Table 1 and
Supplementary Table 1). All 30 subjects completed the study.
ONM-100 was well-tolerated by all 30 subjects with no dose
limiting toxicities or drug-related serious adverse events
(SAEs). Four possible drug-related Common Terminology









pHe = physiological pHe = acidicpH
Fig. 1 Mechanism of action. A tumor microenvironment turns acidic when the tissue transforms from pre-malignant cells into invasive cancer. The ONM-
100 nanoparticles extravasate due to the enhanced permeability of the tumor vasculature and are then retained due to the poor lymph drainage in the
tumor tissue. This leads to ONM-100 accumulation in the acidic extracellular matrix causing the pH activated fluorescence to switch from the “off” (green)
to the “on” (red) state. pHe: extracellular pH, pHt: threshold pH.
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Criteria for Adverse Events (CTCAE) grade 1 adverse events
(AEs) were observed in the 0.3 mg per kg cohort (Table 2).
General blood counts, determined up to day 10, showed no
imaging agent related aberrations. The plasma exposure (C10m
and AUC 0–24 h) of ONM-100 was linearly correlated with the
dose, with an R2 of 0.95 and 0.98, respectively (Supplementary
Fig. 1). The mean terminal-phase half-life in the 1.2 mg per kg
cohort was 44.5 with a standard deviation of 15.8 h. No
differences in pharmacokinetics were observed among the
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Fig. 2 Study design. Intravenous administration of ONM-100 was performed ~24 h (±8 h) prior to surgery. Ten days of safety assessments (laboratory,
pharmacokinetics, ECGs) followed, adverse events were monitored up to day 17 (a). During surgery, intraoperative images were obtained prior to incision
and after excision of the surgical cavity (b). Immediately after excision the specimen was imaged for the presence of a positive surgical margin (c).
Fluorescence images were obtained during all the standard pathology processing phases (d, e), and the H/E slices were correlated with the standard
histopathology slices (f–h). i.v. intravenous, ECG electrocardiogram, H/E hematoxylin eosin, SOC standard of care.
Table 1 Study characteristics.
Tables All
N= 30
0.1 mg per kg
N= 3
0.3 mg per kg
N= 3




1.2 mg per kg
N= 18
Patient characteristics
Age, mean (range) 63 (35–85) 68 (46–80) 53 (35–63) 57 (50–69) 61 (53–78) 65 (34–85)
Males, number (percentage) 8 (27%) 1 (33%) 0 (0%) 1 (33%) 0 (0%) 6 (33%)
Weight, mean (range) 80 (47–113) 62 (53–69) 89 (71–113) 88 (52–119) 87 (73–94) 79 (47–110)
Safety data
AE Grade I 0 0 3 0 0 0
AE > Grade I 0 0 0 0 0 0
Tumor type
BC
Invasive carcicoma NST 7 0 2 1 2 2
Carcinoma with medullary
characteristics
2 0 1 0 0 1a
Mucinous carcinoma 1 0 0 0 0 1
Lobular carcinoma 1 0 0 0 0 1
Invasive micropapillary carcinoma 1 0 0 0 0 1a
HNC
HNSCC 13 3 0 2 1 7
EC
Intestinal adenocarinoma 1 0 0 0 0 1
Mixed adenoneuroendocrine
carcinoma
1 0 0 0 0 1
No viable tumor (after neoadjuvant Tx) 1 0 0 0 0 1
CRC
Intestinal adenocarcinoma 3 0 0 0 0 3
Tumor size
Max diameter, mean (±SD) 2.4 (±1.6) 1.9 (±0.4) 2.2 (±0.8) 3.6 (±1.0) 3.6 (±2.2) 2.1 (±1.6)
Surgical resection margins
Tumor-negative 18 11 2 2 2 1
Tumor-positive 9 4 1 1 1 2
Surgical resection margins are displayed according to the US Guidelines per tumor type. Adverse events are defined as possible imaging agent related adverse events. Source data are provided as a
Source data file.
BC breast cancer, HNC head and neck cancer, HNSCC head and neck squamous cell cancer, EC esophageal cancer, CRC colorectal cancer, SD standard deviation, Tx treatment, NST no special type, AE
adverse event.
aTwo primary tumors from the same subject.
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Summary of fluorescence-imaging results. Viable tumors were
confirmed in a total of 29 of the 30 enrolled subjects by histology.
In each case, a sharp demarcated fluorescent signal was visible
irrespective of the tumor type or dose (Fig. 3) based on the ex vivo
standard fluorescence workflow analysis described previously21
(Fig. 2). We confirmed the tumor specific activation of ONM-100
ex vivo by administering it topically on tissue sections of a freshly
frozen HNSCC specimen (Supplementary Fig. 3). Moreover, no
fluorescence was visible in the blood samples prior to acidification
(Supplementary Fig. 4).
Thirteen HNSCC, the five superficially seated BC tumors and
two CRC tumors were visualized in situ in real time by ONM-100
fluorescence during surgery. All the tumor-positive surgical
margins (9 out of 9) that were undetected during standard of
care (SOC) surgery were visualized during intraoperative
fluorescence imaging and correlated with the final histopatholo-
gical assessment, yielding 100% sensitivity and no false negatives
(Table 3 and Fig. 4). In addition, ONM-100 fluorescence was
detected in five additional occult lesions (in 1 HNSCC and 4 BC
subjects) otherwise missed by the SOC surgery or pathological
analysis. The histologically proven peritoneal metastases (PM) of
the two CRC subjects were fluorescent both in- and ex vivo,
whereas their nonmalignant excised lesions did not fluoresce
(Supplementary Figs. 5 and 6 and Supplementary Movie 1–4).
The tumor-agnostic nature, diagnostic accuracy, and potential
clinical utility of ONM-100 are further described below. Three of
Table 2 Adverse events.
Tumor type Dose cohort Adverse event Grade Intervention Resolved
BC 0.3 mg per kg Headache I No Yes
BC 0.3 mg per kg Pain left cheek I No Yes
BC 0.3 mg per kg Flush I No Yes
BC 0.3 mg per kg Dizziness I No Yes
Adverse events that occurred during the course of the study which were possibly related to imaging agent administration and scored according to the Common Terminology Criteria for Adverse Events
(CTCAE) v4.03: June 14, 2010.
BC breast cancer.
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Fig. 3 Fluorescence images of different tumor tissue slices. Head and neck squamous cell cancer of the tongue (a–f); breast cancer (g–l); esophageal
cancer (m–r); colorectal cancer (s–x). The tumor is delineated as a solid black line in the H/E slices (c, i, o, u). The mean fluorescence intensity (MFI) of the
tumor tissue and the non-tumor tissue slices, per tumor type, is depicted (y). The dots represent the MFI of single tissue slices (≈3 per subject) from the
1.2 mg per kg cohort. HNSCC, 7 subjects, P < 0.0001, BC, 5 subjects, P= 0.0001, EC, 3 subjects, P= 0.0010, and Wilcoxon test, two-sided. CRC,
3 subjects, no statistics performed due to the availability of only three data points. HNSCC head and neck squamous cell cancer, BC breast cancer, EC
esophageal cancer, CRC colorectal cancer, H/E hematoxylin eosin. ***P≤ 0.001; ****P≤ 0.0001. Source data are provided as a Source data file.
Table 3 Contingency table for fluorescence-guided surgical margin assessment.
Tumor-positive resection margin Tumor-negative resection margin
Fluorescence positive 9 5
Fluorescence negative 0 10
Total 9 15
Intraoperative assessment of the surgical margin during fluorescence-guided surgery was either done by intraoperative fluorescence imaging of the surgical cavity or fluorescence imaging of the excised
specimen at the “Back-Table”.
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the BC subjects (27%) had a tumor-positive surgical margin, all of
which were detected by fluorescence imaging. Eight BC subjects
had a proven histopathological tumor-negative surgical margin of
which six were assessed correctly by fluorescence imaging,
corresponding to a sensitivity of 100% and a specificity of 75%
for ONM-100 in this sample size (Supplementary Fig. 7 and
Supplementary Table 2). Of the two BC subjects with a false-
positive fluorescence-imaging result, one subject had a histo-
pathological tumor-negative margin as defined by the ASTRO/
SSO guidelines. However, it contained a ductal carcinoma in situ
(DCIS), an entity with cancer cells within the wall of the ductuli
and, according to international guidelines, might require addi-
tional surgery, underscoring the clinical utility of detecting this
lesion. Hence, it can be debated if this represented a true false-
positive sample. In the other BC subjects with a false-positive
fluorescence-imaging result, the fascia of the larger pectoral
muscle showed a homogenous higher fluorescent signal, as also
described previously21. Regarding the HNSCC cohort, a total of
six subjects (46%) had a histopathologically confirmed tumor-
positive surgical margin, all of which were detected intraopera-
tively by fluorescence. A tumor-negative surgical margin was
confirmed histopathologically in the remaining seven subjects
(54%). Three false-positive fluorescence margins were detected,
which did not contain tumor on final histopathological
examination (Supplementary Fig. 5), resulting in a sensitivity of
100% and a specificity of 57% among the HNSCC subjects
(Supplementary Fig. 7 and Supplementary Table 1).
The ability to detect occult disease such as satellite metastases
and second primary tumors, which are missed by SOC
procedures, exemplifies the potential clinical utility of ONM-
100. This was an ad hoc outcome parameter of the study. A
satellite metastasis in one of the HNSCC subjects was undetected
by SOC surgery but was detected in the surgical cavity by
fluorescence imaging (Supplementary Fig. 5). As discussed above,
the DCIS was detected by ONM-100 fluorescence in the surgical
cavity and back-table in a specimen of a BC subject and was
confirmed by histopathology. Moreover, fluorescence imaging
during histopathological processing detected three additional
otherwise missed cancers in three BC subjects. Of these,
fluorescence imaging enabled the detection of additional satellite
BC metastasis in the surgical specimens of two subjects and a
second primary tumor lesion (triple negative BC) in the third
subject (Supplementary Fig. 5).
One deeper-seated intraluminal rectal, two intraluminal
esophageal, and six deeper-seated breast tumors could not be
visualized intraoperatively due to the near-infrared (NIR)
imaging technology. Notably, however, none of the intraluminal
or deep-seated tumors had a tumor-positive margin on final
histopathology. Importantly, the fluorescence-imaging procedure
did not interfere with the SOC of any of the tested subjects and,
generally, the surgical procedures were only prolonged by a
maximum of 10 min.
Fluorescence quantification and tumor-to-background ratio.
Ex vivo workflow analysis, to further validate the intraoperative
findings, showed that the tumor tissue of all the subjects with
histopathologically proven viable tumor tissue showed a higher
fluorescence signal intensity with sharp morphological delinea-
tions on the tissue slices compared with normal tissue, irre-
spective of tumor type and dose cohort (Fig. 3, panel y and
Supplementary Fig. 6). The tumor tissue’s mean fluorescence
intensity (MFI) increased with dose (Fig. 5, panel a). In all
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Fig. 4 Fluorescence-guided assessment of surgical margins. Representative example of a head and neck squamous cell carcinoma of the tongue from a
subject with a negative surgical margin. In- and ex vivo visualization of fluorescence in the tumor (a, c, g, i) with no fluorescent signal in the surgical cavity
or at the surgical resection margin (b, h, d, j). Correlation of fluorescent signals on a tissue slice with the histology (e, k, f) with a tumor-negative surgical
margin of 6.4 mm. Representative example of breast cancer surgery (i.e., a lumpectomy) with a tumor-positive surgical margin (l, m, n, o). Fluorescence is
detected at the ventral surgical resection margin both in vivo and immediately after excision (r, s, t, u) which corresponds with the fluorescence localization
on the tissue slice (p, v) and the final histopathology (q). The tumor is delineated as a solid black line on the H/E slices (f, q). H/E hematoxylin eosin, SOC
standard of care.
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non-tumor tissue (Fig. 5). The median tumor-to-background
ratio (TBR) of all the tissue slices (n= 97 from 26 subjects) was
4.5 with an interquartile range (IQR) of 3.1 (Fig. 5, panel a). The
optimal dose for tumor detection and sensitivity according to
the Phase 1b studies was 1.2 mg per kg (TBR 4.5, IQR 3.0) and
the MFI of that dose group’s (n= 15) tumor tissue was sig-
nificantly higher compared with normal tissue in each of the
available tissue slices (n= 59, P < 0.0001, Wilcoxon test). A
receiver-operator characteristic (ROC) curve analysis of these
tissue slices showed an area under the curve (AUC) of 0.9875,
P < 0.0001 (Fig. 5, panel g).
An in vivo TBR was calculated for the mucosal tumors
(HNSCC) which were directly exposed to the surface; deeper-
seated tumors gave less reliable results due to overlaying tissue
and differences in absorption and the scattering properties of the
tissue. The median in vivo TBR of the HNSCC subjects in the 1.2
mg per kg group was 2.6 with an interquartile range of 1.4
(representative examples shown in Supplementary Fig. 8).
Discussion
The in and ex vivo data from this fluorescence-imaging study
indicate that the low pH resulting from tumor acidosis can be
exploited as a generic biomarker for cancer in patients with four
different solid tumor types including head and neck squamous cell
carcinoma, breast cancer, esophageal cancer, and colorectal cancer.
The pH-sensitive fluorescent imaging agent ONM-100 was well-
tolerated and was activated by tumor acidosis, delineating tumors
from benign tissues. The initial clinical findings from 30 subjects
provide information about occult cancer which would otherwise not
be obtained by the standard of care (i.e., visual inspection and
palpation alone), which was illustrated by the intraoperative
detection of all the tumor-positive surgical margins (9 out of 9), a
DCIS and a satellite cancer in a head and neck cancer subject as well
as the ex vivo detection of three additional satellite lesions and
second primaries in the pathology specimens.
This Phase I study is the first example of a systemically
administered agent that displays nanoscale cooperativity which
overcomes metabolic and phenotypic variability between different
patients and tumors. Most importantly, and in contrast to
recently studied fluorescence-imaging agents1–8, there was no
overlap between tumor and background fluorescence for any
given subject.
Two features of the reported data are unique. First, while
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Fig. 5 Dose-independent mean fluorescence intensity separation between tumor tissue and non-tumor tissue. Tumor and non-tumor tissue mean
fluorescence intensities (MFI) from the 0.1 mg per kg cohort, P= 0.0005 (a); 0.3 mg per kg cohort, P= 0.0078 (b); 0.5 mg per kg cohort, P= 0.0020 (c);
0.8 mg per kg cohort, P= 0.0078 (d); and 1.2 mg per kg cohort, P < 0.0001, Wilcoxon test, two-sided (e). The dots represent the MFI of single tissue
slices. The receiver-operator characteristics curve is based on the calculated MFI of the tumor and normal tissues from the 1.2 mg per kg dose cohort, P <
0.0001; area under the curve 0.9875, n= 59, with a confidence interval of 95% using Wilson/Brown method (f). ROC receiver operators curve, AUC area
under the curve. **P≤ 0.01; ***P≤ 0.001; ****P≤ 0.0001. Source data are provided as a Source data file.
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use of this physiologic characteristic of cancer has been hampered
by the spatiotemporal variability of pH in tumors and the wide
array of factors that can impact tumor acidity11. We were able to
utilize tumor acidosis in a clinical setting, in diverse cancer types.
Second, although the unique features of nanoscale cooperativity
and non-covalent self-assembly have been long recognized, they
have not been clinically exploited by a systemically administered
agent. The salient features of nanoscale cooperativity, based on
macromolecular non-covalent interactions, include weak and
polyvalent interactions driving self-assembly, the creation of
larger structures that cannot be easily synthesized by covalent
chemistry, faster responses to environmental stimuli due to the
reduced energy barriers, as occurs with covalent bonds, and most
importantly, emergent properties where the system behavior
cannot be predicted by studying the individual components in
isolation23.
Our ex vivo spraying experiments give additional proof of the
specificity of the imaging agent, as these results indicate that no
other mechanism, such as the enhanced permeability and reten-
tion (EPR) effect, other than pH is responsible for fluorescent
activation. This was illustrated by the fact that tumor specific
fluorescence was observed after topical administration of ONM-
100, emphasizing that the EPR effect in vivo is responsible for the
selective accumulation of micelles in the tumor, but the pH of the
tumor is responsible for the opening of the micelle and the
activation of the fluorescence signal. Moreover, mechanical
destruction of the agent can be excluded since no fluorescence
was observed in the plasma samples of patients without
acidification.
A potential drawback might be the activation of ONM-100 by
other mechanisms associated with a lowered pH, such as in
inflammatory tissue24. Some tumors present with a peri-tumoral
inflammatory rim as part of the defense mechanism of the innate
immune system to the invading tumor cells25. In this study, we
did not observe this phenomenon in this small series of speci-
mens. However, we believe that, if this occurs, it has a minimal
impact, and it might actually provide a fluorescent rim sur-
rounding the actual tumor-positive margin, and thus serve the
clinical applicability in fluorescence-guided surgery.
Biomarkers like HIF-1-α26, CA-IX27, and VEGF-A11, among
others, all play a significant role in the development and main-
tenance of tumor acidosis. As activation of ONM-100 relies on
tumor acidosis in general, and is not dependent on one specific
biomarker, immunohistochemical staining would only give lim-
ited information on the molecular mechanism of fluorescence
activation. It would be beneficial to correlate the in vivo data with
the microscopic distribution of the fluorescence data. Unfortu-
nately, this was not feasible in the current clinical trial since
ONM-100 is not membrane-bound and the fluorescence was
washed out during the standard of care processing of tissues.
Invasive pH measurements to correlate the localization of fluor-
escence with pH within and surrounding the tumor was deemed
neither feasible nor safe in this Phase 1 clinical trial due to the
following reason: undertaking pinpoint invasive pH measure-
ments in the tumor can influence the integrity of the surgical
specimen, potentially hampering standard of care histopatholo-
gical evaluation. A possible remedy for this, in future studies,
could be pH measurements with, for example, chemical exchange
saturation transfer magnetic resonance imaging (CEST-MRI)28 in
patients who receive ONM-100.
The timing of the administration of ONM-100 was kept con-
sistent, to 24 h prior to surgery in this Phase 1 feasibility and
imaging study, to prevent heterogeneity in the imaging data and
was chosen based on pre-clinical data17. A different dose-to-
imaging interval is being investigated in an ongoing Phase 2 study
of ONM-100, since administration only a few hours prior to
surgery might be preferable in terms of clinical implementation.
In addition, higher dosages could be investigated in subsequent
studies, since this might further improve TBRs. Moreover, our
results indicate that ONM-100 could be utilized in a broad variety
of other solid tumor types.
Clinical success can be improved when surgeons are provided
with a more accurate and unambiguous delineation of the cancer
location in addition to the extensive information on the locations
of the tumors from conventional ultrasound, CT, PET, or MR
imaging. The ability of an optical imaging output to improve
surgical outcomes is predicated on delivering information the
surgeon does not have from pre-operative imaging and intrao-
perative inspection29 by vision and palpation alone. The combi-
nation of tumor acidosis as a general phenomenon and the
cooperativity of ONM-100 has the potential to adequately
improve surgical guidance in a variety of tumors using fluores-
cence. The broader implication is that nanoscale macromolecular
cooperativity can exploit a labile physiologic parameter for clin-
ical purposes. Other biologic parameters (e.g., hypoxia, redox
potential) which were previously unexploitable due to unpre-
dictable variability may also be amenable to clinical targeting
based on this chemical principle, representing a new therapeutic
paradigm.
Nanoscale macromolecular cooperativity, which responds to
pH changes from cancer acidosis, is demonstrated to be safe and
clinical utility of the ONM-100 imaging agent for intraoperative
and ex vivo detection of cancer is shown in this study. The results
of our clinical study serve as a proof of principle that physiologic
parameters such as pH, which were previously inaccessible
therapy targets, may become clinically relevant through the
application of macromolecular cooperativity.
Methods
GMP synthesis of the pH-activatable micelles. Clinical grade pH-activatable
ONM-100 was released from the Good Manufacturing Practice (GMP) facility of
Bioserv Corporation, San Diego, USA, under FDA regulated conditions. The
product was shipped to PCI Pharma Services, Bridgend, UK, for distribution to the
Hospital Pharmacy Trial Bureau of the University Medical Center Groningen
(UMCG), The Netherlands. A detailed description of the production process was
published by a previous study17. Briefly, ONM-100 consists of polymeric micelles
labeled with IndoCyanine Green (ICG). Chemically, the ONM-100 drug substance
comprises a diblock copolymer of polyethyleneglycol (PEG) (~113 repeating units)
and a poly(methyl methacrylate) derivative covalently conjugated to functionalized
ICG as the fluorophore. The ICG content was determined by a qualified method
from its molecular weight of 37.5 ± 12.5 kD. Vials containing 9 mg ONM-100 drug
substance formulated in sterile water for injection with 10% (v/w) trehalose were
used to prepare infusions at a concentration of 3 mg/ml. After the final product was
released by the certified qualified person (QP) at the UMCG Hospital Pharmacy
facility, the imaging agent was intravenously administered to the subjects.
Subject population. The subjects included in this first-in-human clinical study had
histologically proven primary or recurrent HNSCC, BC, EC, or CRC. Subjects were
eligible if they were 18 years of age or older, and their hematological status was
acceptable as was their kidney and liver function. The subjects had to abstain from
alcohol intake during the study period (from 24 h before to 17 days after imaging
agent administration). Any subjects receiving neoadjuvant therapy prior to surgery
were excluded from Phase 1a. Other exclusion criteria were an inability to give
informed consent, participation in another clinical trial with an investigational
product, inadequately controlled hypertension, history of allergic or infusion
reaction to iodine, iodine-based contrast, shellfish, or ICG, those receiving
potentially highly hepatotoxic medication, pregnancy, and subjects with magne-
sium, potassium, and calcium lower than the lower normal limit.
Clinical trial design. This dose-finding Phase 1 study was performed in two
medical centers and enrolled 30 subjects from March 2018 until December 2018.
The study, conducted in both the University Medical Center Groningen (UMCG,
Groningen, The Netherlands) and the Martini Hospital Groningen (MZH, Gro-
ningen, The Netherlands) was approved by the Institutional Review Board (IRB) of
the UMCG (METc Number 2017/580).
The study was conducted according to the Dutch Act on Medical Research
involving Human Subjects (WMO) and to the principles of the Declaration of
Helsinki (adapted version Fortaleza, Brazil, 2013). All the subjects were identified
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by the respective multi-disciplinary tumor boards of the participating hospitals.
After a pre-screening, the eligible subjects were orally informed and received
written information about the study. All the participants gave written informed
consent before the start of any related study procedure. An independent medical
monitor was assigned to review the screening safety assessments prior to
enrollment. Serious adverse events, if present, were immediately reported to the
IRB, the medical monitor and the Dutch central committee on research involving
human subjects (CCMO) and were followed up until resolved or a stable medical
situation was achieved. The trial was registered at the Netherlands National Trial
Register (NTR number 7085) and within the European Clinical Trials Database
(EudraCT 2017-003543-38). Primary outcomes were safety, pharmacokinetics, and
imaging feasilibity of ONM-100. Secondary outcomes were to determine a range of
safe doses of ONM-100 for intraoperative imaging using commonly used
fluorescence camera systems. The complete study was divided in two phases, Phase
1a and Phase 1b, respectively. We adhered to the FDA guidelines (Guidance for
Industry, Developing Medical Imaging Drug and Biological Products, Part 2
Clinical Indications) when designing the Phase 1a dose-finding protocol, followed
by setting a dose expansion cohort (15 subjects, Phase 1b). Five different doses were
used in an escalating/de-escalating scheme (i.e., 0.3 mg per kg, 0.5 mg per kg,
0.8 mg per kg, 0.1 mg per kg, and 1.2 mg per kg) and administered to three subjects
each. In Phase 1a, only subjects with histologically proven HNSCC and BC were
included to minimize tumor heterogeneity and to collect information about the
potential tumor-agnostic characteristics of ONM-100. After dosing each cohort, a
dose escalation meeting was held with the principal investigators, sub-investigators,
and the sponsor’s medical monitor to make sure the escalation to a higher dose was
safe. The most optimally performing dose was 1.2 mg per kg in Phase 1a, based on
tumor visualization and safety data. The additional 15 subjects included in Phase
1b were studied to confirm the safety and to evaluate the tumor-agnostic properties
of ONM-100 imaging in additional solid tumor types (EC, CRC) to HNSCC and
BC. In both phases, the subjects received a single dose of ONM-100 24 ± 8 h prior
to surgery. All doses were injected intravenously at 15 mg per min. After the
injection, the infusion line was flushed with 5 ml sterile water.
Safety measurements. A primary outcome of our study was to measure the safety
of ONM-100. The subjects underwent a medical screening procedure before
enrollment in the study, consisting of vital signs measurements, a physical exam-
ination, a standard 12-lead electrocardiogram (ECG), and laboratory tests
(including a serum pregnancy test of women of childbearing potential). Once
enrolled, an ECG was performed 1 h and 10 days after the ONM-100 infusion (the
latter only in Phase 1a). Lab tests were performed before and after administration
(day 1, 2, 3, and 10). The vital signs and physical examinations were measured
before and after imaging agent injection (5 min, 1 h, day 2, 3, and 10). The subjects
were asked about signs and symptoms before and after the injection (5 min, 1 h,
3 h, 8 h, day 2, 3, 10, and 17). Standard postoperative checkups were arranged for
within 2 weeks after surgery. During these visits, wound healing and adverse events
were monitored as well. Adverse event assessment was performed according to the
National Cancer Institute CTCAE version 4.0.
Pharmacokinetic assessments. An additional primary outcome was to measure the
pharmacokinetics of ONM-100. Blood samples were collected for pharmacokinetic
(PK) analysis prior to, and after 10min, 30min, 1 h, 3 h, 8 h, 24 h, 48 h, 72 h, and
240 h of intravenous administration of ONM-100. The blood was collected in 4mL
BD K2EDTA vacutainers and stored directly on ice. The samples were then cen-
trifuged at 1500 × g for 10min and divided into three vials under cold conditions. The
vials were stored in a −80 degrees Celsius freezer in the UMCG and then transported
on dry ice to Intertek Pharmaceutical Services (San Diego, California, USA).
The ONM-100 plasma concentrations were determined using a validated direct
fluorescence reader assay (Intertek Pharmaceutical Services, San Diego, California,
USA) and the PK analysis was performed by Pacific BioDevelopment (Davis,
California, USA). Plasma concentration versus time profiles were generated for each
subject. The PK parameters were estimated using Phoenix WInNonlin (version 8.0).
The estimated parameters were C10m, Cmax, Tmax, AUClast, AUCall, and AUC 0-
24hr. Values below the level of quantitation (<10 μg/ml, BQL) were set to 0.
The linear trapezoid method was used for the estimation of the area under the
plasma concentration versus time curves from dosing to the last time point with a
measurable concentration (AUClast). The last three or more time points were used
to estimate the elimination rate constant (λz) which was used to estimate the
terminal-phase half-life (T ½).
Surgical procedure (standard of care). All the subjects underwent surgical
removal according to the standard surgery protocols of both hospitals for each
respective tumor type. Dependent on the tumor type and/or stage, a sentinel lymph
node biopsy (lymph node mapping using 99mTechnetium and perioperative
detection using a gamma-probe) or a lymph node dissection was performed on
some of the subjects. Based on prior experience using fluorescence-guided surgery
at the UMCG and MZH, there was minimal interference with the standard of care.
As described earlier, the use of methylene blue was avoided and the use of fluor-
escent skin markers and (green) fluorescent sterile drapes was minimized21 due to
the potential interference with ONM-100.
Intraoperative fluorescence-imaging devices. A secondary outcome of our study
was to investigate different imaging systems. Two open-surgery intraoperative
fluorescent camera systems were used in this study to detect ONM-100, namely the
Explorer Air® (SurgVision B.V., Groningen, The Netherlands) and the SPY Elite®
(Stryker, Kalamazoo, MI, USA). When performing minimally invasive surgery (e.g.,
robot assisted esophagectomy or diagnostic laparoscopic surgery for peritoneal
metastasis), clinically available near-infrared (NIR) imaging systems were used
namely, the Olympus NIR Laparoscope (Olympus, Sjinjuku, Tokyo, Japan) and the
Intuitive Da Vinci Firefly robot NIR laparoscope (Intuitive Surgical, Sunnyvale,
CA, USA).
The Explorer Air®, which provides real-time simultaneous fluorescence and
white light (color) images, is currently undergoing CE-marking in Europe and is
only available in the European and US markets for experimental use. Fluorescence
is excited by NIR light emitting diodes (LEDs) with an excitation peak of 760 nm.
Filtered white light is used to illuminate the color images. A software user interface
enables the user to control the camera settings and to display the color and
fluorescence images. The output is that both still images and movies can be
recorded and stored in a TIFF format. Although the excitation peak is not
optimized for ICG detection, ICG is efficiently detected due to overlapping light
spectra. The working distance of the imaging system was set at 20 cm above the
surgical field. All images were obtained with a fluorescence exposure time of 100
ms and a 100 gain. If oversaturation occurred, the exposure time was lowered to 50
or 25 ms but if it persisted, the gain was lowered to 10.
The SPY Elite provides real-time fluorescence and white light imaging. The
system is CE-marked for ICG detection and is commercially available. NIR light
from the illumination module in the imaging console is transmitted to the imaging
head via fiber-optic cables. The SPY Elite has an excitation peak of 805 nm. A
software user interface enables the user to control the camera settings and to
capture white light images and fluorescence movies. The working distance of the
imaging system was set at 30 cm above the surgical field. All images were obtained
with a frame rate of 7.5 per second. White light images and fluorescence movies
were recorded and stored from the SPY Elite in AVI/PNG format.
The Da Vinci Firefly and the Olympus NIR Laparoscope provide real-time
fluorescence and white light images. Both systems, which have an excitation peak
of 805 nm, are CE-marked for ICG detection and are commercially available. A
software user interface is provided. The working distance of the imaging system
was set at 2–20 cm above the surgical field. As described earlier, all the
intraoperative camera systems were calibrated using a calibration disk21
(CalibrationDisk©, SurgVision BV, The Netherlands). The ICG used in the
CalibrationDisk© was stabilized by dissolving it in methanol and it was then diluted
to different concentrations ranging from 0.005 mg per ml to 1.5 mg per ml to check
whether the systems could detect low and high fluorescent signals and as a
diagnostic test of the systems.
Fluorescence-imaging systems for ex vivo imaging. To further validate the
intraoperative imaging feasibility as a primary outcome, we used the the closed-
field macroscopic fluorescence PEARL-trilogy® imaging device (Li-COR BioS-
ciences Inc., Lincoln, NE, USA), which is designed for ex vivo fluorescence ima-
ging. A charge-coupled device (CCD) camera detects fluorescence in the NIR
wavelength with a peak emission at 785 nm. The 11.2 cm × 8.4 cm field of view and
the focus point can be adjusted based on specimen height. The same resolution
setting was used (85 µm) for all the specimens throughout the study.
Intraoperative imaging procedures. A secondary outcome of our study was to
investigate different imaging systems. All standard of care surgical procedures had
priority over study related procedures. Fluorescence imaging was performed at pre-
defined time points: (i) just before the first incision; (ii) when tumor visibility was
most optimal, as judged by the surgeon (e.g., after lump preparation for a lumpect-
omy); (iii) after excision of the surgical cavity to inspect for remaining fluorescent
spots. If fluorescent spots were detected, the surgeon was allowed to biopsy these
spots; (iv) on all the resection planes after excising the specimen to check for the
presence of fluorescent spots. An intraoperative fluorescence margin assessment
entails a combination of the fluorescence image of the surgical cavity and the fluor-
escence image of the excised specimen within 1 h after excision. The surgeon was able
to look at a second monitor to evaluate the fluorescence images while performing the
surgical procedure. During the imaging procedure, the ambient light in the surgical
theater was switched off to prevent possible interaction with the fluorescence-imaging
procedure itself. The standard of care was not influenced or altered by the imaging
procedures. Regarding intrathoracal esophageal imaging, only extraluminal fluores-
cence imaging of the tumor and resection plane was performed.
In vivo TBR was calculated for all the HNSCC subjects whose mucosal tumors
had been directly exposed to the intraoperative camera. We only calculated the
in vivo TBRs for the HNSCC subjects because the other tumors (BC, EC, CRC)
were deeper-seated and thus (a) not visible or (b) no reliable calculation could be
done due to overlying tissue and differences in optical tissue properties. The mean
fluorescence intensity (MFI) of both the tumor and background areas was
calculated. The MFI was based on a region of interest (ROI) which was carefully
determined based on a macroscopic examination. The TBR was calculated as
tumor ROI (MFI tumor)/background ROI (MFI non-tumor tissue) per tissue slice.
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The median TBR was calculated on a per subject base. The data (MFI, TBR) were
plotted as graphs using GraphPad Prism, version 8.
Specimen handling. According to the SOC, the specimen was marked using
sutures to aid orientation during tissue processing and cross-correlation with the
histopathology immediately after excision. The exact location of the suture was
tumor type and surgeon-dependent and was carefully documented to correlate
fluorescence signals with tissue orientation.
(Freshly) excised surgical specimen imaging procedures. The specimens were
stored, as much as possible, in the dark during all the tissue processing phases to
prevent possible photobleaching of the imaging agent. All the surgical specimens
were handled to conform to the standard of care which was not affected by study
related procedures.
Immediately after excision all six resection planes of the specimen were imaged,
size allowing (e.g., frontal, dorsal, lateral, medial, caudal, and cranial) by both the
intraoperative camera system of choice as well as the PEARL-trilogy® system with a
maximum duration of 60 min after surgical excision of the specimen. The
combined imaging time of both devices was a maximum of 5 min. The specimens’
resection planes were marked with blue and black ink. The use of other ink colors
was avoided since these might interfere with the fluorescence in the NIR range. The
restricted use of two colors of ink did not affect the standard of care for tissue
processing by the pathologist but, if a third ink color was needed, green ink was
used to define additional pathological resection margins of interest.
The fluorescence-imaging time points were adapted due to the SOC differences
in specimen processing of the different tumor types. Briefly, the fresh BC
specimens were sliced on the day of surgery and then formalin fixed whereas the
other tumor types were sliced after formalin fixation of the whole resection
specimen 1–3 days after surgery. The surgical specimen was serially sliced into
±0.5-cm-thick tissue slices. White light photographs were made during and directly
after slicing for orientation purposes. After slicing, both sides of each tissue slice
underwent fluorescence imaging in a light-tight environment (PEARL-trilogy®).
The BC slices were therefore imaged ~120 min after excision. The other tumor
types were imaged after formalin fixation and thus 1–3 days after excision.
Subsequently, a pathologist blinded for the recorded fluorescence images,
examined the tissue slices macroscopically. This involved a gross examination by
visual inspection and palpation alone and the selected regions of interest were
embedded in paraffin blocks for further standard of care histological analysis.
Other tissue samples that had not been selected by gross examination were
embedded based on high fluorescent intensity spots or regions. In line with Koller
et al., a standardized workflow was executed in order to cross-correlate the final
histopathology results with the recorded fluorescence images of the tissue slices of
interest21. Subsequently, hematoxylin/eosin (H/E) stained 4-μm sections were
produced and analyzed by a board-certified pathologist who was also blinded for
the obtained fluorescent imaging data.
Quantification of ONM-100 fluorescence in tissue slices. To further validate
the intraoperative imaging feasibility as a primary outcome, the images of both
sides of the respective tissue slices collected with PEARL-trilogy® were used to
calculate the mean fluorescence intensity (MFI) of both tumor and background
areas. The MFI was based on a Region of Interest (ROI) which was carefully
determined on the H/E 4-μm slides by a board-certified pathologist blinded for the
fluorescent imaging data and subsequently overlayed precisely on the corre-
sponding tumor and normal tissue slices. Non-tumor tissue was considered to be
any other tissue than the tumor tissue in the respective tissue slice. No distinction
was made between specific non-tumor tissue types when defining the background.
TBR was calculated as tumor ROI (MFI tumor)/background ROI (MFI non-tumor
tissue) per tissue slice. A median TBR was calculated on a per subject base. The
data (MFI, TBR) were plotted as graphs using GraphPad Prism, version 8.
Specific ex vivo activation experiments. An activation buffer (0.1 M sodium
acetate-acetic acid) or phosphate-buffered saline (PBS) was added to human
plasma with a certain concentration of ONM-100 and mixed with 20X PBS in a 96-
well plate. The fluorescence was measured using a plate reader (TECAN Infinite
M200 PRO, Männedorf, Switzerland).
The tumor was collected with adjacent stromal tissue during surgery and
immediately frozen in optimal cutting temperature compound (OCT). It was cut
into 8 μm frozen sections and sprayed with a fluorescent pH sensor (ICG was
substituted with a tetramethylrhodamine (TMR) dye) and incubated for 3 min.
After 10 min of fixation with formalin, the slides were washed three times with
0.9% NaCL+ 0.5% Tween 20. The sections were DAPI stained and scanned for
fluorescence (Zeiss Axio slide scanner, Oberkochen, Germany). Adjacent slides
were H/E stained for histopathological correlation purposes.
Statistical analysis. The H/E sections, as shown in the respective figures, cor-
respond to the tissue as shown in the adjacent panels. Note that from all
included tissue slides, a corresponding H/E section has been cut and evaluated
by the pathologist for correlating the fluorescence images to histolopathology.
The MFI was calculated, using Image J Fiji, as total counts per ROI pixel area in
both the tumor and background non-tumor tissues. The data was tested for
Gaussian distribution using Anderson–Darling and Shapiro–Wilk tests; none of
the data were normally distributed. Differences in fluorescence intensities
between dose cohorts were tested using a Wilcoxon statistical test. The data are
presented as median and interquartile ranges. A receiver-operator curve (ROC)
was calculated using Graphpad Prism, version 8. A P value <0.05 was regarded as
statistically significant. GraphPad Prism, version 8 was used for the statistical
analyses.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All the data (imaging data, safety data, and pharmacokinetic data) gathered and/or
processed during this study are available from the corresponding author on request. The
source data (individual data points) underlying Figs. 3 and 5, Table 1 and Supplementary
Figs. 1, 2, 4, and 6 are provided as a Source data file. All other data are available within
the Article and Supplementary information.
Received: 4 February 2020; Accepted: 27 May 2020;
References
1. van Dam, G. M. et al. Intraoperative tumor-specific fluorescence imaging in
ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat.
Med. 17, 1315–1319 (2011).
2. Harlaar, N. J. et al. Molecular fluorescence-guided surgery of peritoneal
carcinomatosis of colorectal origin: a single-centre feasibility study. Lancet
Gastroenterol. Hepatol. 1, 283–290 (2016).
3. Lamberts, L. E. et al. Tumor-specific uptake of fluorescent bevacizumab-
IRDye800CW microdosing in patients with primary breast cancer: a phase I
feasibility study. Clin. Cancer Res. 23, 2730–2741 (2017).
4. Rosenthal, E. L. et al. Safety and tumor specificity of cetuximab-IRDye800 for
surgical navigation in head and neck cancer. Clin. Cancer Res. 21, 3658–3666
(2015).
5. Gao, R. W. et al. Determination of tumor margins with surgical specimen
mapping using near-infrared fluorescence. Cancer Res. 78, 5144–5154
(2018).
6. Hoogstins, C. E. S. et al. Image-guided surgery in patients with pancreatic
cancer: first results of a clinical trial using SGM-101, a novel carcinoembryonic
antigen-targeting, near-infrared fluorescent agent. Ann. Surg. Oncol. 25,
3350–3357 (2018).
7. Whitley, M. J. et al. A mouse-human phase 1 co-clinical trial of a protease-
activated fluorescent probe for imaging cancer. Sci. Transl. Med. 8, 320ra4
(2016).
8. Hoogstins, C. E. S. et al. A novel tumor-specific agent for intraoperative near-
infrared fluorescence imaging: a translational study in healthy volunteers and
patients with ovarian cancer. Clin. Cancer Res. 22, 2929–2938 (2016).
9. Voskuil, F. J. et al. Fluorescence-guided imaging for resection margin
evaluation in head and neck cancer patients using cetuximab-800CW: a
quantitative dose-escalation study. Theranostics 10, 3994–4005 (2020).
10. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546–1558 (2013).
11. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell
144, 646–674 (2011).
12. Gatenby, R. A. & Gillies, R. J. Why do cancers have high aerobic glycolysis?
Nat. Rev. Cancer 4, 891–899 (2004).
13. Webb, B. A., Chimenti, M., Jacobson, M. P. & Barber, D. L. Dysregulated
pH: a perfect storm for cancer progression. Nat. Rev. Cancer 11, 671–677
(2011).
14. Delli Castelli, D., Ferrauto, G., Cutrin, J. C., Terreno, E. & Aime, S. In vivo
maps of extracellular pH in murine melanoma by CEST-MRI. Magn. Reson
Med. 71, 326–332 (2014).
15. Wike-Hooley, J. L., Haveman, J. & Reinhold, H. S. The relevance of tumour pH
to the treatment of malignant disease. Radiother. Oncol. 2, 343–366 (1984).
16. Ma, X. et al. Ultra-pH-sensitive nanoprobe library with broad pH tunability
and fluorescence emissions. J. Am. Chem. Soc. 136, 11085–11092 (2014).
17. Zhao, T. et al. A transistor-like pH nanoprobe for tumour detection and
image-guided surgery. Nat. Biomed. Eng. 1, 1–8 (2016).
18. Li, Y. et al. Molecular basis of cooperativity in pH-triggered supramolecular
self-assembly. Nat. Commun. 7, 13214 (2016).
19. Huang, G. et al. PET imaging of occult tumours by temporal integration of
tumour-acidosis signals from pH-sensitive (64)Cu-labelled polymers. Nat.
Biomed. Eng. 4, 314–324 (2020).
20. Hensley, C. T. et al. Metabolic heterogeneity in human lung tumors. Cell 164,
681–694 (2016).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-16814-4 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:3257 | https://doi.org/10.1038/s41467-020-16814-4 |www.nature.com/naturecommunications 9
21. Koller, M. et al. Implementation and benchmarking of a novel analytical
framework to clinically evaluate tumor-specific fluorescent tracers. Nat.
Commun. 9, 37–39 (2018).
22. Warburg, O., Wind, F. & Negelein, E. The metabolism of tumors in the body. J
Gen Physiol. 8, 519–530 (1927).
23. Li, Y., Wang, Y., Huang, G. & Gao, J. Cooperativity principles in self-
assembled nanomedicine. Chem. Rev. 118, 5359–5391 (2018).
24. Rajamaki, K. et al. Extracellular acidosis is a novel danger signal alerting
innate immunity via the NLRP3 inflammasome. J. Biol. Chem. 288,
13410–13419 (2013).
25. Fridman, W. H. et al. Prognostic and predictive impact of intra- and
peritumoral immune infiltrates. Cancer Res. 71, 5601–5605 (2011).
26. Gillies, R. J. & Gatenby, R. A. Hypoxia and adaptive landscapes in the
evolution of carcinogenesis. Cancer Metastasis Rev. 26, 311–317 (2007).
27. Pastorekova, S. & Gillies, R. J. The role of carbonic anhydrase IX in cancer
development: links to hypoxia, acidosis, and beyond. Cancer Metastasis Rev.
38, 65–77 (2019).
28. Jones, K. M., Pollard, A. C. & Pagel, M. D. Clinical applications of chemical
exchange saturation transfer (CEST) MRI. J. Magn. Reson Imaging 47, 11–27
(2018).
29. Hadjipanayis, C. G., Jiang, H., Roberts, D. W. & Yang, L. Current and future
clinical applications for optical imaging of cancer: from intraoperative surgical
guidance to cancer screening. Semin Oncol. 38, 109–118 (2011).
Acknowledgements
The authors want to thank all the participating subjects. Next, we would like to thank
Gert-Jan Meersma, Nadine Baan and the Department of Pathology for their technical
assistance, physician assistants Clara Lemstra, Arieke Prozee, Jacqueline Biermann, and
Rachel Dopheide for their help in recruiting subjects, and Cristina Sala Ripoll for her help
with the illustrations.
Author contributions
F.J.V., P.J.S., M.K., B.D.S., and Y.J. designed the study. F.J.V. and P.J.S. performed the
data acquisition, analyzed and interpreted the data and drafted the paper. T.Z. and J.G.
designed the polymer composition of ONM-100. B.v.d.V. and J.J.D. were involved in the
histopathological analyses and the reviewing of the paper. Members of the SHINE study
group performed the fluorescence-imaging procedures, histopathological analyses and/or
critically revised the paper. G.M.v.D. and M.J.H.W. designed and supervised the study,
interpreted the data, and drafted the paper. All the authors reviewed the final paper. The
research was funded by OncoNano Medicine Inc. J.G. and B.D.S. received National
Institutes of Health funding (R01 CA192221, R01 CA211930).
Competing interests
B.D.S. and J.G. are advisors, Y.J., T.Z., and Y.A. are employees and N.S. is a consultant
at OncoNano Medicine Inc. B.D.S., J.G., Y.J., T.Z., Y.A., and N.S. are shareholders of
OncoNano Medicine Inc. J.P.H. is an owner of JPH Clinical Development Inc and is a
consultant at OncoNano Medicine Inc. The research was funded by OncoNano
Medicine Inc. G.M.v.D. is a member of the Scientific Advisory Board of SurgVision
BV as well as the CEO, founder, and shareholder of AxelaRx/TRACER BV. The
sponsor (OncoNano Medicine Inc.) participated in the study design, the data
were analyzed independently of the sponsor. The sponsor delivered technical advice
for writing the paper (B.D.S. and J.G.). All other authors declare no competing
interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-
020-16814-4.
Correspondence and requests for materials should be addressed to B.D.S. or G.M.v.D.
Peer review information Nature Communications thanks Joachim Klode and the other,
anonymous, reviewer(s) for their contribution to the peer review of this work. Peer
reviewer reports are available.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2020
the SHINE study group
Y. Albaroodi3, L. B. Been2, F. Dijkstra2, B. van Etten2, Q. Feng6, R. J. van Ginkel2, K. Hall3, K. Havenga2,
J. W. Haveman2, P. H. J. Hemmer2, L. Jansen2, S. J. de Jongh9, G. Kats-Ugurlu4, W. Kelder10, S. Kruijff2,
I. Kruithof11, E. van Loo2, J. L. N. Roodenburg1, N. Shenoy12, K. P. Schepman1 & S. A. H. J. de Visscher1
9Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, The Netherlands. 10Department of Surgery,
Martini Hospital Groningen, Groningen, The Netherlands. 11Department of Pathology, Martini Hospital Groningen, Groningen, The Netherlands.
12Aravasc Inc., Sunnyvale, CA 94089, USA.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-16814-4
10 NATURE COMMUNICATIONS |         (2020) 11:3257 | https://doi.org/10.1038/s41467-020-16814-4 | www.nature.com/naturecommunications
